ArticleEndocrine, metabolic & immune disorders drug targets2026
Exploration of the Mechanism of Erchen Decoction in Ameliorating Obesity by Regulating Lipid Deposition
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionObesity, a global health crisis, necessitates innovative therapeutic strategies. Traditional Chinese Medicine (TCM), including Erchen Decoction (ECD), offers potential benefits; however, the molecular mechanisms underlying ECD's anti-obesity effects, particularly on lipid metabolism, remain unclear. This study investigates the mechanism by which ECD improves lipid metabolism through the AMPK/SIRT1/PGC-1α signaling pathway.
methodsAML-12 hepatocytes were cultured and divided into Control, Model (palmitic acid-induced lipid deposition), and treatment groups (ECD serum: 2%, 4%, 8%; orlistat: 10 μM). Cell viability, lipid accumulation, and triglyceride (TG) content were measured. Key lipid metabolism genes (p-AMPK/AMPK, SIRT1, PPARα, PGC-1α, Nrf2, TFAM) were evaluated using RT-qPCR, Western Blot, and immunofluorescence. Network pharmacology analysis identified ECD's targets and pathways.
resultsThe Model group showed increased lipid droplets and TG content, with reduced AMPK, SIRT1, PPARα, PGC-1α, Nrf2, and TFAM expression compared to Control. ECD treatment significantly decreased lipid droplets and TG content (at all doses), with the 4% dose being the most effective. ECD up-regulated all tested genes, confirmed by immunofluorescence (p-AMPK, SIRT1, PGC-1α). Network pharmacology highlighted the overlap between ECD and obesity pathways, with a particular emphasis on lipid metabolism. DISCUSSION: ECD improves lipid metabolism in AML-12 hepatocytes by activating the AMPK/ SIRT1/PGC-1α pathway, consistent with prior research. The upregulation of Nrf2 and TFAM indicates enhanced mitochondrial function and resistance to oxidative stress. Limitations include the use of in vitro models; future studies should focus on clinical translation and dosage optimization.
conclusionECD regulates lipid metabolism via the AMPK/SIRT1/PGC-1α pathway, providing a scientific basis for its clinical use in obesity-related diseases. This study highlights ECD as a promising therapeutic strategy for improving lipid metabolism and reducing obesity-associated risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.